Perspectives on purine analogues

Hematology and Cell Therapy

Volumn 38, Issue SUPPL. 2, 1996, Pages

  Cheson, B D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cladribine; CLL; fludarabine; NHL; pentostatin

Indexed keywords

CLADRIBINE; FLUDARABINE; PENTOSTATIN; PURINE DERIVATIVE;

HUMAN; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; REVIEW;

ANTINEOPLASTIC AGENTS; CLADRIBINE; FORECASTING; HUMANS; LEUKEMIA; PENTOSTATIN; PURINES; VIDARABINE;

EID: 0029825528     PISSN: 14302772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Al-Katib, A, Mohammed RM, Dan M, Hussein ME, Akhtar A, Pettit GR, Sensenbrenner LL (1993) Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp Hematol 21 : 61-65
2. Anaissie, E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M (1992) Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 117 : 466-469
3. Betticher, DC, Fey MF, von Rohr A, Tobler A, Jenzer H, Gratwohl A, Lohri A, Pugin P, Hess U, Zulian G, Cerny T (1994) High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 5 : 57-64
4. Betticher, DC, Zucca E, von Rohr A, Egger T, Radford JA, Ambrosetti A, Búrki K, Rufener B, Hsu Schmitz SF, Cerny T (1996) 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol (in press)
5. Beutler, E (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340 : 952-956
6. Beutler, E, Koziol JA, McMillan R, Sipe JC, Romine JS, Carrera CJ (1994) Marrow suppression produced by repeated doses of cladribine. Acta Haematol 91 : 10-15
7. Bhalla, K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y (1993) Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7 : 563-568
8. Blagosklonny, MV, Schulte T, Nguyen P, Trepel J, Neckers LM (1996) Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56 : 1851-1854
9. Boumpas, DT, Cheson BD, Fessler BJ, Adams EM, Scott DE (Submitted for publication) Purine nucleoside analogs: bridging the gap between indolent lymphoid malignancies and systemic autoimmune diseases
10. Carrera, CJ, Piro LD, Saven A, Beutler E, Terai C, Carson DA (1991) 2-Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. In RA Harkness (ed) Purine and pyrimidine metabolism in man. Plenum Press, New York, pp 15-18
11. Carson, DA, Seto S, Wasson DB, Carrera CJ (1986) DNA strand breaks, NAD metabolism, and programmed cell death. Exp Cell Res 164 : 273-281
12. Carson, DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB (1992) Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2́-arabino- fluoro-2́-deoxyadenosine. Proc Natl Acad Sci 89 : 2970-2974
13. Cassileth, PA, Cheuvart B, Spiers ASD, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ (1991) Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 9 : 243-246
14. Cheson, BD (1992) The purine analogs - a therapeutic beauty contest. J Clin Oncol 10 : 868-871
15. Cheson, BD (1995) Immunologic and immunosuppressive complications of purine analogue therapy. J Clin Oncol 13 : 2431-2448
16. Cheson, BD (1996) Ennui or not ennui, that is the question? Ann Oncol (in press)
17. Cheson, BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR (1996) National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 : 4990-4997
18. Cheson, BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA (1988) Guidelines for clinical protocols for chronic lymphocytic leukemia: Report of the NCI-sponsored Working Group. Am J Hematol 29 : 152-163
19. Cheson, BD, Vena D, Foss F, Sorensen JM (1994) Neurotoxicity of purine analogs: a review. J Clin Oncol 12 : 2216-2228
20. Chun, HG, Leyland-Jones B, Cheson BD (1991) Fludarabine phosphate: A synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 9 : 175-188
21. Cummings, FJ, Kim K, Neiman RS, Comis RL, Oken MM, Weitzman SA, Mann RB, O'Connell MJ (1991) Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 9 : 565-571
22. Delia, D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T, Reed JC, Pierotti MA (1995) Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregualted bcl-2. Blood 85 : 359-367
23. Dimopoulos, MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R (1994) Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12 : 2694-2698
24. Dimopoulos, MA, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Baralogie B, Alexanian R, Keating MJ (1993) Fludarabine therapy in Waldenström's macroglobulinemia. Am J Med 95 : 49-52
25. Drexler, HG, Gignac SM, Jones RA, Scott CS, Pettit GR, Hoffbrand AV (1989) Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 74 : 1747-1757
26. Duggan, DB, Anderson JR, Dillman R, Case D, Gottlieb AJ (1990) 2′Deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: A CALGB phase II study. Med Ped Oncol 18 : 203-206
27. Elias, L, Stock-Novack D, Head DR, Grever MR, Weick JK, Chapma RA, Godwin JE, Metz EN, Appelbaum FR (1993) A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study. Leukemia 7 : 361-365
28. Estey, E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymph 9 : 343-350
29. Estey, EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO, Stass S, Freireich EJ (1992) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79 : 882-887
30. Filleul, B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P, Sokal G, Martiat P, Michaux JL (1994) A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8 : 1153-1156
31. French Cooperative Group on CLL, Johnson S, Smith AG, Löffler H, Ösby E, Juliusson G, Emmerich B, Wyid PJ, Hiddemann W (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 347 : 1432-1438
32. Gandhi, V, Nowak B, Keating MJ, Plunkett W (1989) Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy. Blood 74 : 2070-2075
33. Grégoire, V, Hunter N, Milas L, Brock WA, Plunkett W, Hittelman WN (1994) Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res 54 : 468-474
34. Grégoire, V, Van NT, Stephens C, Brock WA, Milas L, Plunkett W, Hittelman WN (1994) The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 54 : 6201-6209
35. Grever, M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WEN, Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson BD (1995) A randomized comparison of pentostatin vs alpha-interferon in previously untreated patients with hairy cell leukemia: an inter-group study. J Clin Oncol 13 : 974-982
36. Hakimian, D, Tallman MS, Kiley C, Peterson L (1993) Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoryadenosine for hairy cell leukemia. Blood 82 : 1798-1802
37. Hickish, T, Serafinowski P, Cunningham D, Oza A, Dorland E, Judson I, Millar BC, Lister TA, Roldan A (1993) 2′-Chlorodeoxyadenosine: evaluation of a novel predominately lymphocyte selective agent in lymphoid malignancies. Br J Cancer 67 : 139-143
38. Hiddemann, W, Rottmann R, Wormann B, Thiel A, Essink M, Ottensmeier C, Freund M, Buchner T, van de Loo J (1991) Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study. Ann Hematol 63 : 1-4
39. Hiddemann, W, Unterhalt M, Pott C, Wormann B, Sandford D, Freund M, Engert A, Gassmann W, Holtkamp W, Seufert J, Hellriegel K-P, Knauf W, Emmerich B, Kanz L, Koch P (1993) Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German Low-grade Non-Hodgkin's Lymphoma Study Group. Sem Oncol 20 [Suppl 7] : 28-31
40. Hochster, H, Oken M, Bennett J, Wolff B, Gordon L, Raphael B, Gencarelli P, Cassileth P (1994) Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first-line therapy of low-grade non-Hodgkin's lymphomas (NHL) - ECOG 1491 (abstract 1517). Blood 84 [Suppl 1] : 383a
41. Hochster, HS, Kim K, Green MD, Mann RB, Neiman RS, Oken MM, Cassileth PA, Stott P, Ritch P, O'Connell MJ (1992) Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10 : 28-32
42. Hoffman, M, Tallman MS, Hakimian D, Janson D, Hogan D, Variakogis D, Kuzel T, Gordon LI, Rai K (1994) 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 12 : 788-792
43. Johnston, JB, Verburg L, Shore T, Williams M, Israels LG, Begleiter A (1994) Combination therapy with nucleoside analogs and alkylating agents. Leukemia 8 [Suppl 1] : S140-143
44. Juliusson, G, Christiansen I, Hansen MM, Johnson S, Kimby E, Elmhorn-Rosenberhg A, Liliemark J (1996) Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 14 : 2160-2166
45. Juliusson, G, Heldal D, Hippe E, Hedenus M, Malm C, Wallman C, Stolt C-M, Evensen SA, Albertioni F, Tjennfjord G, Lenkei R, Liliemark J (1995) Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 13 : 989-995
46. Juliusson, G, Lenkei R, Tjonnfjord G, Heldal D, Liliemark J (1995) Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: Predictive factors and effects of granulocyte-macrophage colony-stimulating factor. Ann Oncol 6 : 371-375
47. Juliusson, G, Liliemark J (1993) High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease in blood lymphocyte count. J Clin Oncol 11 : 679-689
48. Kantarjian, HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ (1990) Fludarabine therapy in macroglobulinemic lymphoma. Blood 75 : 1928-1931
49. Kay, AC, Saven A, Carrera CJ, Piro LD (1992) 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 10 : 371-377
50. Keating, MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ (1993) Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81 : 2878-2884
51. Kernena, A, Keating MJ, Plunkett W (1991) Plasma and cellular bioavailability of oral fludarabine (abstract 199). Blood 78 [Suppl 1] : 52a
52. Kitada, S, Andersen J, Hines J, Rai K, Cassileth P, Reed JC (1995) Expression of bcl-2 family genes and in vitro sensitivity to fludarabine and 2-chlorodeoxyadenosine in B-CLL (abstr 2417). Blood 86 [Suppl 1] : 607a
53. Kobayashi, K, Vogelzang NJ, O'Brien SM, Schilsky RL, Vokes EE, Ratain MJ (1994) A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer 74 : 168-173
54. Kraut, EH, Grever MR, Bouroncle BA (1994) Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 84 : 4061-4063
55. Kurtzberg, J, Keating MJ, Plunkett W, Gandhi V, Gold S, Reese M, Elion G, Mitchell B (1996) Compound 506 (2-amino-6-methoxypurine arabinoside) is active against resistant T-cell malignancies: preliminary results of an ongoing phase I trial (abstract 2022). J Clin Oncol 14 : 1750
56. Larson, RA, Mick R, Spielberger RT, O'Brien SM, Ratain MJ (1996) Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol 14 : 188-195
57. Leiby, JM, Grever MR, Staubus AE, Neidhart JA, Malspeis L (1988) Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous infusion schedule. J Natl Cancer Inst 80 : 447-449
58. Cooperative Group for the Study of Immunoglabulin in Chronic Lymphocytic Leukemia (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 319 : 902-907
59. Liliemark, JO, Albertioni F, Pettersson B, Juliusson G (1992) Bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine (CdA) (abstract 270). Proc Am Soc Clin Oncol 11 : 112
60. Malspeis, L, Staubus AE, Lyon ME, Gloff CA, Tessman DK (1989) Oral bioavailability of 2-F-ara-A from fludarabine phosphate capsules in dogs (abstract 2124). Proc Am Assoc Cancer Res 30 : 534
61. McLaughlin, P, Grillo-Lopez A, Czuczman M, Link BK, Levy R, Dillman RO, Ho A, Bennett JM, Heyman MR, Schilder RJ, Cabanillas F, Rogers J, Dallaire BK (1996) Preliminary report on a phase III pivotal trial of the anti-CD20 antibody (MAB) IDEC-C2B8 in patients (PTS) with relapsed low-grade or follicular lymphoma (LG|F NHL) (abstract 1281). Proc ASCO 15 : 417
62. McLaughlin, P, Hagemeister FB, Romaguerra JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F (1996) Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma trial. J Clin Oncol 14 : 1262-1268
63. McLaughlin, P, Hagemeister FB, Swan F Jr., Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M (1994) Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12 : 575-579
64. Menzel, T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R, Gabrilove J (1996) Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87 : 1056-1063
65. Molica, S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, Levato D, Nobile F, Carotenuto M, Liso V, Rotoli B (1990) Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 81 : 121-126
66. Moskowitz, C, Offit K, Straus D, Portlock C (1994) Fludarabine in stage IV low grade non-Hodgkin's lymphoma (LGL): the Memorial Hospital experience (abstract 1284). Proc ASCO 13 : 379
67. O'Brien, S, Kantarjian H, Beran M, Lerner S, Gilbreath J, Keating MJ (1996) Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL) (abstract 214). Int J Hematol 64 [Suppl 1] : S56
68. O'Brien, S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82 : 1695-1700
69. Ohno, R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K (1990) An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8 : 1907-1912
70. Pigaditou, A, Rohatiner AZS, Whelan JS, Johnson PWM, Ganjoo RK, Rossi A, Norton AJA, Amess J, Lim J, Lister TA (1993) Fludarabine in low-grade lymphoma. Sem Oncol 20 [Suppl 7] : 24-27
71. Piro, LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322 : 1117-1121
72. Piro, LD, Petroni G, Barcos M, Johnson J, Saven A, Peterson B (1995) Bolus infusion 2-chlorodeoxyadenosine (2-CdA) as first-line therapy of low-grade non-Hodgkin's lymphoma (NHL): CALGB 9153 (abstract 1082). Blood, 86 [Suppl 1] : 274a
73. Ponnathpur, V, Tang C, Reed JC Huang Y, Willingham M, Ray S, Bullock G, Bhalla K (1993) Mechanisms of resistance to Taxol induced apoptosis in human leukemic cells (abstract 1007). Blood 82 [Suppl 1] : 255a
74. Preti, HA, Plunkett W, Sarris AH, Younes A, Hagemeister F, Rodriguez MA, Romaguera J, McLaughlin P, Bachier C, Cabanilias F (1995) Preliminary results of a phase II trial of topotecan in patients with relapsing lymphoma (abstract 3268). Blood 86 [Suppl 1] : 820a
75. Puccio, CA, Mittelman A, Lichtman SM, Silver RT, Budman DR, Ahmed T, Feldman EJ, Coleman M, Arnold PM, Arlin ZA, Chun HG (1991) A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 9 : 1562-1569
76. Rai, KR, Peterson B, Elias L, Shepherd L, Hines J, Nelson D, Cheson B, Kolitz J, Schiffer CA (1996) A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTC/NCI-C and ECOG inter-group study. Blood 88 [Suppl 1] : in press
77. Rai, KR, Peterson B, Kolitz J, Elias L, Shephard L, Hines J, Cheson B, Schiffer C (1995) Fludarabine induces high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL) (abstract 2414). Blood, 86 [Suppl 1] : 607a
78. Redman, JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F Jr., Rodriguez MA, Plunkett WK, Keating MJ (1992) Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 10 : 790-794
79. Robertson, LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, Plunkett W (1993) Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl fluoroadenine. Blood 81 : 143-150
80. Robertson, LE, O'Brien S, Koller C, Beran M, Feldman E, Kantarjian H, Hagemeister F, Andreef M, Lerner S, Plunkett W, Keating MJ (1992) A three-day schedule of fludarabine in chronic lymphocytic leukemia (CLL) (abstract 177). Blood 80 [Suppl 1] : 47a
81. Saven, A, Carrera CJ, Carson DA, Beutler E, Piro LD (1991) 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymph 5 [Suppl] : 133-138
82. Saven, A, Cheung WK, Smith I, Moyer M, Johannsen T, Rose E, Gollard R, Kosty M, Miller WE, Piro LD (1996) Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 4 : 978-983
83. Saven, A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L (1995) 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 86 : 1710-1718
84. Saven, A, Kawasaki H, Carrera C, Waltz T, Copeland B, Zyroff J, Kosty M, Carson DA, Beutler E, Piro LD (1993) 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol 11 : 671-678
85. Saven, A, Lee T, Kosty M, Piro L (1996) Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol 14 : 2139-2144
86. Saven, A, Piro LD (1992) Treatment of hairy cell leukemia. Blood 79 : 1111-1120
87. Sipe, JC, Romine JS, McMillan R, Zyroff J, Beutler E (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344 : 9-13
88. Solal-Céligny, P, Brice P, Brousse N, Caspard H, Bastion Y, Haioun C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau JL, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Lepporier M (1996) Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14 : 514-519
89. Sorensen, JM, Vena D, Fallavollita A, Chun HG, Cheson BD (1996) Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C mechanism of the National Cancer Institute: 5-year follow-up report. J Clin Oncol : (in press)
90. Tallman, MS, Hakimian D, Rademaker AW, Zanzig C, Wollins E, Rose E, Peterson L (1996) Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 88 : 1954-1959
91. Tefferi, A, Witzig TE, Reid JM, Li C-Y, Ames MM (1994) Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol 12 : 569-574
92. Varterasian, M, Eilender D, Mohammed R, Chen B, Hulburd K, Rodriguez D, Pluda J, Valdivieso M, Al-Katib A (1996) Phase I trial of bryostatin 1 in relapsed lymphoma and CLL (abstract 1526). Proc ASCO 15 : 481
93. Weeks, JC, Tierney MR, Weinstein MC (1991) Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia, N Engl J Med 325 : 81-86
94. Weiss, M, Spiess T, Berman E, Kempin S (1994) Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 8 : 1290-1293
95. Wheaton, S, Tallman MS, Hakimian D, Peterson L (1996) Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 87 : 1556-1560
96. Whelan, JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AB, Catovsky D, Rohatiner AZS, Lister TA (1991) Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 64 : 120-123
97. Wilson, WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jaffe ES, Steinberg SM, Goldspeil BR, Cheson BD, Wittes RE (1995) Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 13 : 381-386
98. Wilson, WH, Pearson D, Humphrey R, Kohler D, Steinberg S (1996) A phase II and dose escalation study ± G-CSF of 9-amino-camptothecin (9-AC) in relapsed lymphoma. Proc 9th NCI-EORTC symposium on new drugs in cancer therapy (abstract 464). pp 131
99. Yang, E, Korsmeyer SJ (1996) Molecular thanaptosis: A discourse on the BCL2 family and cell death. Blood 88 : 386-401
100. Younes, A, Ayoub J-P, Hagemeister FB, McLaughlin P, Sarris A, Rodriguez MA, Swan F Jr., Romaguera JE, Martin J, Cabanillas F (1996) No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol 14 : 543-348
101. Younes, A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L, Smith TL, Cabanillas F (1995) Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 13 : 583-587
102. Zinzani, PL, Bendandi M, Tura S (1995) FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. Eur J Haematol 55 : 262-266
103. Zinzani, PL, Lauria F, Rondelli D, Benfenati D, Raspadori D, Bocchia M, Bendandi M, Gozzetti A, Zaja F, Fanin R, Russo D, Galieni P, Tura S (1993) Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4 : 575-578
104. Zinzani, PL, Ricci P, Bendandi M, Tura S (1995) 2-Chlorodeoxyadenosine in psoriasis treatment (letter). Ann Oncol 5 : 509